Randomized clinical trial data have demonstrated that omission of surgical axillary evaluation does not affect overall survival in women 70 years and older with early-stage (clinical tumor category 1 [cT1] with node-negative [N0] disease) hormone receptor (HR)–positive and erb-B2 receptor tyrosine kinase 2 (ERBB2; formerly HER2)–negative breast cancer. Here, ERBB2 is linked to neoplasm.